MGIM
BPMC

M&G Investment Management’s Blueprint Medicines BPMC Stock Holding History

M&G Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,937
Closed -$509 – 519
2021
Q3 		$509 Sell
4,937
-3,431
-41% -$320K ﹤0.01% 677
2021
Q2 		$736 Buy
+8,368
New +$767K ﹤0.01% 649

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

M&G Investment Management's BPMC Position: Q4 2021 in Review

M&G Investment Management sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 4,937 shares — an estimated $509 sold.

M&G Investment Management first reported a position in BPMC in Q2 2021 and held it in 2 quarters. The position peaked at $736 in Q2 2021. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • M&G Investment Management reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • M&G Investment Management sold 4,937 Blueprint Medicines shares in Q4 2021, an estimated $509.
  • M&G Investment Management first reported a position in Blueprint Medicines in Q2 2021 and held it in 2 quarters.
  • M&G Investment Management's Blueprint Medicines position peaked at $736 in Q2 2021.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.